Nicotine receptor agonists in stem cell and progenitor cell recruitment
AssigneeThe Board of Trustees of the Leland Stanford, Jr. Unversity
InventorsJohn Cooke, Frances Lauri Johnson, Anjali Pathak, James Jang, Phillip Tsao, Christopher Heeschen
Life of this patent
Estimating the term…
Abstract
The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).
Claims16
A method of mobilizing a progenitor cell in a mammal, the method comprising administering to a mammal a nicotine receptor agonist in an amount effective to stimulate mobilization of a progenitor cell from bone marrow of the mammal to a site of deficiency or injury in the mammal, wherein the nicotine receptor agonist is nicotine, a nicotine salt, a nicotine derivative, a nicotine metabolite, or a derivative of a nicotine metabolite.
A method of treating a condition amenable to treatment by recruitment of bone marrow-derived progenitor cells, the method comprising:
- administering to a mammal a nicotine receptor agonist in an amount effective to stimulate mobilization of a progenitor cell from bone marrow of the mammal to a site of deficiency or injury in the mammal, wherein the nicotine receptor agonist is nicotine, a nicotine salt, a nicotine derivative, a nicotine metabolite, or a derivative of a nicotine metabolite.
Dependencies are inferred from the claim text.